Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 11

Results For "Head"

1544 News Found

Zota Health Care expands Davaindia network to 1,530 stores
Healthcare | March 20, 2025

Zota Health Care expands Davaindia network to 1,530 stores

The company has also launched its first three 24*7 pharmacy stores via COCO model in Bengaluru


Healthcare Triangle appoints Sujatha Ramesh as COO
People | March 20, 2025

Healthcare Triangle appoints Sujatha Ramesh as COO

Previously, Sujatha has held leadership positions at prominent organizations, including Publicis Sapient, Infinite Computer Solutions, and Capgemini


Aerogen opens India HQ in New Delhi
News | March 20, 2025

Aerogen opens India HQ in New Delhi

The new office in New Delhi marks a significant funding in the APAC region and reinforces the company’s commitment to advancing respiratory care in India


Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset
News | March 18, 2025

Shilpa Biologicals partners with mAbTree Biologics AG for a novel immunooncology asset

This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation


CKD cases surge to 16.38% in Indians aged 15+
Healthcare | March 17, 2025

CKD cases surge to 16.38% in Indians aged 15+

Experts urge early detection & better access to care


OneSource Specialty Pharma strengthens its board by appointing new directors
People | March 13, 2025

OneSource Specialty Pharma strengthens its board by appointing new directors

These appointments align with the group’s philosophy of having a strong and independent board with exceptional industry experts, ensuring strategic guidance and effective governance


Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


Biocon Biologics announces positive results from Phase 3 study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis
Diagnostic Center | March 08, 2025

Biocon Biologics announces positive results from Phase 3 study of Yesintek biosimilar to Ustekinumab for chronic plaque psoriasis

The study demonstrated equivalent efficacy, safety, immunogenicity, and pharmacokinetics between YESINTEK and the reference product Stelara